Akèy › Limfom Difize Gwo Selil B › Lwizyàn
Etid klinik pou Limfom Difize Gwo Selil B nan Lwizyàn
6 etid pou Limfom Difize Gwo Selil B ap chèche patisipan nan sit nan Lwizyàn.
Vil nan Lwizyàn
Tèks ofisyèl etid la (Anglè)
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Mary Bird Perkins Cancer Center, Baton Rouge
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05006716A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Our Lady of the Lake Physician Group-Medical Oncology ( Site 0180), Baton Rouge
- Ochsner LSU Health - Monroe Medical Center, Family Medicine Clinic ( Site 0209), Monroe
- Ochsner Clinic Foundation ( Site 0189), New Orleans
- ak 1 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06890884A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- CHRISTUS St. Frances Cabrini Hospital Center for Cancer Care ( Site 0184), Alexandria
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06717347Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Mary Bird Perkins Cancer Ctr, Baton Rouge
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06806033Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Louisiana State University Health Sciences Center, Shreveport
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT05826535DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Tulane Cancer Center Office of Clinical Research, New Orleans
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Apr 7, 2023 · NCT04920617Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.